Cepheid, a Danaher company announced the publication of a study demonstrating the real-world impact of the Xpert Xpress MVP (multiplex vaginal panel) test when used at the point of care.

The study showed that significantly more women with vaginitis symptoms (e.g., abnormal discharge, odor, itching, or discomfort) received appropriate treatment within 24 hours of their clinic visit when tested with Xpert Xpress MVP compared to standard diagnostic methods. Standard methods are still common in clinical practice and include symptom-based assessment and microscopy.

This study is the first randomized clinical trial to evaluate the utility of a multiplex molecular test for vaginitis at the point of care. The research was led by investigators at Magee-Womens Research Institute and the University of Pittsburgh and was supported by an investigator-initiated grant from Cepheid.

Key findings:

• 89.6% of women tested with Xpert Xpress MVP received appropriate treatment within 24 hours of their clinic visit compared to 51.9% with usual care (p < 0.001).
• Among symptomatic women confirmed with no infection, 50% in the usual care arm received unnecessary antimicrobial treatments compared to 27.1% in the Xpert Xpress MVP arm (p = 0.031).
• Most healthcare providers in the study with patients randomized to Xpert Xpress MVP were satisfied with the turnaround time and workflow.

This study provided insight into real-world diagnostic practices for vaginitis. The investigators reported that 25% of providers relied solely on symptoms to guide treatment decisions, and standard approaches correctly identified infections only about 50–63% of the time. These findings reinforce longstanding challenges associated with microscopy-based diagnosis, including inconsistent use and variable accuracy.

Visit Cepheid for more information